http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고아라,위서리,Ji In Ryu,Hien Thi Thu Do,이연정,임수정,이인모,정대인,박진아,최정아,송만기,이나경 대한약학회 2018 Archives of Pharmacal Research Vol.41 No.2
Adjuvants are essential vaccine componentsused to enhance, accelerate, and/or prolong adaptiveimmunity against specific vaccine antigens. In this study,we compared the adjuvanticity of two adjuvant formulationscontaining de-O-acylated lipooligosaccharide(dLOS), a toll-like receptor 4 agonist, on the Japaneseencephalitis (JE) vaccine in mice. Mice were immunizedonce or twice at a two-week interval with inactivated JEvaccine in the absence or presence of adjuvant. We foundthat both the alum- and the liposome-based formulationinduced significantly faster and higher serum IgG antibodyresponses as compared with the non-adjuvanted vaccineafter either one or two immunizations. The antibody titersof the mouse immune sera correlated with 50% plaquereduction neutralization test (PRNT50) antibody titers. Inaddition, the dLOS/liposome formulation was more effectivein inducing a Th1-type immune response than thedLOS/alum formulation, as suggested by a strong antigenspecificinterferon (IFN)-c response. Based on theseresults, we suggest that both alum- and liposome-basedadjuvant formulations containing dLOS may be used forthe development of JE vaccines with improvedimmunogenicity.
Kwon Kee Woong,Kang Tae Gun,Lee Ara,Jin Seung Mo,Lim Yong Taik,Shin Sung Jae,하상준 대한면역학회 2023 Immune Network Vol.23 No.2
Bacillus Calmette-Guerin (BCG) vaccine is the only licensed vaccine for tuberculosis (TB) prevention. Previously, our group demonstrated the vaccine potential of Rv0351 and Rv3628 against Mycobacterium tuberculosis (Mtb) infection by directing Th1-biased CD4+ T cells co-expressing IFN-γ, TNF-α, and IL-2 in the lungs. Here, we assessed immunogenicity and vaccine potential of the combined Ags (Rv0351/Rv3628) formulated in different adjuvants as subunit booster in BCG-primed mice against hypervirulent clinical Mtb strain K (Mtb K). Compared to BCG-only or subunit-only vaccine, BCG prime and subunit boost regimen exhibited significantly enhanced Th1 response. Next, we evaluated the immunogenicity to the combined Ags when formulated with four different types of monophosphoryl lipid A (MPL)-based adjuvants: 1) dimethyldioctadecylammonium bromide (DDA), MPL, and trehalose dicorynomycolate (TDM) in liposome form (DMT), 2) MPL and Poly I:C in liposome form (MP), 3) MPL, Poly I:C, and QS21 in liposome form (MPQ), and 4) MPL and Poly I:C in squalene emulsion form (MPS). MPQ and MPS displayed greater adjuvancity in Th1 induction than DMT or MP did. Especially, BCG prime and subunit-MPS boost regimen significantly reduced the bacterial loads and pulmonary inflammation against Mtb K infection when compared to BCG-only vaccine at a chronic stage of TB disease. Collectively, our findings highlighted the importance of adjuvant components and formulation to induce the enhanced protection with an optimal Th1 response.